Are androgen receptor variants a substitute for the full-length receptor?

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Nat Rev Urol

Title: Nature reviews. Urology

ISSN (Electronic): 1759-4820

ISSN (Print): 1759-4812

Publication date (Electronic): Mar 2015

Volume: 12

Issue: 3

Affiliations

[1 ] Department of Urology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.

[2 ] Department of Urology, Mayo Clinic, 200 First Street SW Rochester, MN 55905, USA.

[3 ] Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Article

Publisher Item ID: nrurol.2015.13

DOI: 10.1038/nrurol.2015.13

PubMed ID: 25666893

SO-VID: 930f8098-f32b-4cf0-95c5-a9a568d9874b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 50

See all cited by

- Version 1